Our approach


Success through collaboration

Formulation Development Drug Prodcut

Coriolis has 13+ years of experience in successfully formulating a large variety of different (bio)pharmaceutical drug substances, including proteins, peptides, nucleic acids, ATMPs, GMOs, vaccines and virus(-like) particles. This gives us in-depth knowledge about each molecule type or class. We combine this with existing knowledge from our clients about their particular drug substance and take into account the target product profile (TPP), the current stage of drug development, timelines and availability of material and resources.

With this combination, our experts generate a tailor-made and phase-appropriate formulation development strategy for each project - being it a one-factor-at-a-time (OFAT) or design-of-experiment (DOE) approach. Each project will be supported by one of our distinguished scientific advisors, who will be actively involved in project discussions from the very beginning to the end and will contribute with their long-year experience to a successful outcome. 

Our experts - your success

Multi-disciplinary project teams are composed individually for each project depending on the required skills and expertise and will consist to 100% of academic staff. The project leader you will interact with, is also the person conducting the experiments in the lab together with his team. That way, you get first-hand information straight from the source. The scientific knowledge of our experts is independent and accountable and supported by our internal scientific research group, which publishes multiple peer-reviewed scientific articles each year.

Drug substances


Antibodies, hormones and other therapeutic proteins

Nucleic acids

DNA, RNA and oligonucleotides

Advanced therapy medicinal products (ATMPs)

Gene- and cell therapy products and other GMOs


Oligopeptides, peptide hormones, and small proteins

Vaccines & viruses

Viral vectors, mRNA vaccines, virus-like particles and more.

Small molecules

Synthetic or biological small molecules

Contact us

Contact us

For enquiries related to our approach please contact Dr. Sylvia Bold-Haupenthal

Dr. Sylvia Bold-Haupenthal